Antibody molecules which bind CD79
The present disclosure relates to antibody molecules comprising a binding domain specific to CD79, said binding domain comprising SEQ ID NO: 1, 2, 3 or 4, and/or SEQ ID NO: 5, 6 and 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
1. An antibody molecule comprising a binding domain specific to human CD79b wherein the binding domain comprises a heavy chain variable domain (VH),
wherein the VH comprises:
a CDRH1 of SEQ ID NO:8 or 11,
a CDRH2 of SEQ ID NO:9 or 12,
a CDHR3 of EPYEPYDDSNIYYGMDP (SEQ ID NO: 3) or DAGHSDVDVLDI (SEQ ID NO: 4), and
a light chain variable domain (VL),
wherein the light chain variable domain (VL) comprises:
a CDRL1 of SEQ ID NO:13 or 19;
a CDRL2 of SEQ ID NO:14 or 20;
a CDRL3 independently selected from the group consisting of SEQ ID NO: 15, 16, 17, 18, 21, 22, 23 and 24.
2. The antibody molecule according to claim 1 wherein CDRH1 is SEQ ID NO:8, CDRH2 is SEQ ID NO:9, CDRH3 is SEQ ID NO:4, CDRL1 is SEQ ID NO:13, CDRL2 is SEQ ID NO:14 and CDRL3 is independently selected from SEQ ID NO:15, 16, 17 and 18.
3. The antibody molecule according claim 1 , wherein VH and VL are humanised.
4. The antibody molecule according to claim 3 wherein the variable domain of the heavy chain (VH) comprises a human framework region wherein the residue at at least one of positions 24, 37, 48, 49, 67, 71, 73 and 78 according to Kabat numbering is a donor residue and the variable domain of the light chain (VL) comprises a human framework region wherein the residue at at least one of positions 2, 3, 36, 46, 49 and 70 according to Kabat numbering is a donor residue.
5. The antibody molecule according to claim 3 comprising
a. a VH having the sequence given in SEQ ID NO:34 or 35 and a VL having the sequence given in SEQ ID NO:33 or 250 or
b. a VH having the sequence given in SEQ ID NO:41 or 42 and a VL having the sequence given in SEQ ID NO:40, 341, 342 or 343.
6. The antibody molecule according to claim 1 , wherein the antibody is:
a. a full length antibody or
b. a scFv, Fv, Fab or Fab′fragment.
7. The antibody molecule according to claim 1 , wherein the molecule format is selected from diabody, scdiabody, triabody, tandem scFv, FabFv, Fab′Fv, FabdsFv, Fab-scFv, Fab-dsscFv, Fab-(dsscFv) 2 diFab, diFab′, tribody, tandem scFv-Fc, scFv-Fc-scFv, scdiabody-Fc, scdiabody-CH3, Ig-scFv, scFv-Ig, V-Ig and Ig-V.
8. The antibody molecule according to claim 6 further comprises a binding domain which is specific to CD22.
9. The antibody molecule according to claim 8 wherein each binding domain is monospecific.
10. The antibody molecule according to claim 8 wherein:
a. the bispecific or trispecific molecule comprises no more than one binding domain which is specific to CD22 and no more than one binding domain which is specific to CD79b; or
b. the binding domain which is specific to CD22 and the binding domain which is specific to CD79b are independently selected from a Fab, scFv, Fv, dsFv and dsscFv.
11. The antibody molecule according to claim 1 in which one or more binding domains are humanised.
12. The antibody molecule according to claim 1 , which further comprises a binding domain specific to serum albumin.